Bryan A. Mehlhaff

403 total citations
22 papers, 287 citations indexed

About

Bryan A. Mehlhaff is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Bryan A. Mehlhaff has authored 22 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 6 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Oncology. Recurrent topics in Bryan A. Mehlhaff's work include Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Hormonal and reproductive studies (4 papers). Bryan A. Mehlhaff is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Hormonal and reproductive studies (4 papers). Bryan A. Mehlhaff collaborates with scholars based in United States, Canada and United Kingdom. Bryan A. Mehlhaff's co-authors include Neal D. Shore, Michael E. Moran, Mark White, Daniel R. Saltzstein, Paul Sieber, Tracy McGowan, Huiling Pei, Yu‐Ning Wong, Ronald Tutrone and Fred Saad and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

Bryan A. Mehlhaff

20 papers receiving 280 citations

Peers

Countries citing papers authored by Bryan A. Mehlhaff

Since Specialization

Citations

This map shows the geographic impact of Bryan A. Mehlhaff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan A. Mehlhaff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan A. Mehlhaff more than expected).

Fields of papers citing papers by Bryan A. Mehlhaff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan A. Mehlhaff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan A. Mehlhaff. The network helps show where Bryan A. Mehlhaff may publish in the future.

Co-authorship network of co-authors of Bryan A. Mehlhaff

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan A. Mehlhaff. A scholar is included among the top collaborators of Bryan A. Mehlhaff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan A. Mehlhaff. Bryan A. Mehlhaff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK. 2024 ·Journal of Clinical Oncology ·Stephen J. Freedland, Paul Sieber, Martin Gleave, Ugo De Giorgi, Bryan A. Mehlhaff, Daniel C. Danila, Curtis Dunshee, Costas D. Lallas, (unknown), Yiyun Tang, Gabriel P. Haas, Matt Rosales, Jamal Tarazi, Fabian Zohren, David Russell, Neal D. Shore	0
2	Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer 2023 ·Advances in Therapy ·Neal D. Shore, Bryan A. Mehlhaff, Michael S. Cookson, Daniel R. Saltzstein, Ronald Tutrone, Bruce Alan Brown, Sophia Lu, Mark Fallick, (unknown), Fred Saad	4
3	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer 2022 ·Clinical Cancer Research ·Christopher J. Sweeney, Ivor Percent, Sunil Babu, Jennifer L. Cultrera, Bryan A. Mehlhaff, Oscar B. Goodman, David Morris, Ian D. Schnadig, Costantine Albany, Neal D. Shore, Paul Sieber, Susan C. Guba, Yaoguang Zhang, Volker Wacheck, Gregory P. Donoho, Anna M. Szpurka, Sophie Callies, Boris K. Lin, Johanna C. Bendell	31
4	Hereditary cancer risk assessment and genetic testing in the community urology practice setting 2022 ·The Prostate ·Neal D. Shore, (unknown), Elizabeth S. Cogan, Diana Iliev, (unknown), Darl D. Flake, Stephanie Meek, Thaylon Davis, Karen Copeland, (unknown), (unknown), Howard Korman, (unknown), Laurence Belkoff, Mark Jalkut, Neil Mariados, (unknown), Bryan A. Mehlhaff, Thomas P. Slavin, Todd Cohen	2
5	PD35-08 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: POOLED SAFETY ANALYSES FROM RANDOMIZED CONTROLLED STUDIES 2022 ·The Journal of Urology ·James L. Bailen, Fred Saad, (unknown), Bryan A. Mehlhaff, Michael S. Cookson, Daniel R. Saltzstein, Ronald Tutrone, Bruce Brown, Andria Langenberg, Sophia Lu, Jina Lee, Sarah Hanson, Bertrand Tombal, Neal D. Shore	0
6	Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study. 2022 ·Journal of Clinical Oncology ·Neal D. Shore, Daniel J. George, Bryan A. Mehlhaff, Michael S. Cookson, Daniel R. Saltzstein, Ronald Tutrone, Bruce Alan Brown, Sophia Lu, Jina Lee, (unknown), Fred Saad	1
7	A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide 2021 ·ESMO Open ·Daniel P. Petrylak, Ulka N. Vaishampayan, (unknown), Celestia S. Higano, Costantine Albany, Nancy A. Dawson, Bryan A. Mehlhaff, David I. Quinn, Luke T. Nordquist, (unknown), Jonathan Siegel, Lucia Trandafir, Oliver Sartor	6
8	The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial 2020 ·European Urology ·David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, Lawrence I. Karsh, Bryan A. Mehlhaff, Christopher Pieczonka, James L. Bailen, Hongliang Shi, Zhan Ye, Hélène M. Faessel, Huamao Mark Lin, Yanyan Zhu, Fred Saad, David B. MacLean, Neal D. Shore	50
9	Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States 2019 ·Urology ·Jeremy B. Shelton, (unknown), (unknown), (unknown), (unknown), (unknown), Bryan A. Mehlhaff, Ronald Suh, Timothy Bradford, Alec S. Koo, (unknown), Neal D. Shore	10
10	Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United States 2019 ·Urology ·Jeremy B. Shelton, (unknown), Richard R. Augspurger, Franklin Gaylis, Todd Cohen, Bryan A. Mehlhaff, Ronald Suh, Timothy Bradford, (unknown), Alec S. Koo, Neal D. Shore	6
11	Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT) 2019 ·Clinical Genitourinary Cancer ·Neal D. Shore, Daniel R. Saltzstein, Paul Sieber, Bryan A. Mehlhaff, (unknown), Jennifer Phillips, Yu‐Ning Wong, Huiling Pei, Tracy McGowan	35
12	Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT): Results. 2018 ·Journal of Clinical Oncology ·Neal D. Shore, Daniel R. Saltzstein, Paul Sieber, Bryan A. Mehlhaff, (unknown), Jennifer L. Phillips, Yu‐Ning Wong, Huiling Pei, Tracy McGowan	9
13	eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer 2017 ·Clinical Genitourinary Cancer ·Neal D. Shore, Ronald Tutrone, Neil Mariados, Luke T. Nordquist, Bryan A. Mehlhaff, (unknown), (unknown)	23
14	Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC) 2016 ·Annals of Oncology ·David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, Lawrence I. Karsh, Bryan A. Mehlhaff, Christopher Pieczonka, James L. Bailen, David B. MacLean, Serap Sankoh, Hélène M. Faessel, Huamao Mark Lin, Neal D. Shore	7
15	LB-S&T-12 OPEN -LABEL PHASE II STUDY EVALUATING THE EFFICACY OF CONCURRENT ADMINISTRATION OF RADIUM RA 223 DICHLORIDE AND ABIRATERONE ACETATE IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH SYMPTOMATIC BONE METASTASES (ERADICATE) 2016 ·The Journal of Urology ·Neal D. Shore, Ronald Tutrone, Luke T. Nordquist, Neil Mariados, Bryan A. Mehlhaff, (unknown)	4
16	Experimental Utilization of the Holmium Laser in a Model of Ureteroscopic Lithotripsy: Energy Analysis 1999 ·Journal of Endourology ·(unknown), Michael E. Moran, Mark White, (unknown), Bryan A. Mehlhaff	9
17	URETERAL STRICTURE FORMATION FOLLOWING REMOVAL OF IMPACTED CALCULI 1999 ·The Journal of Urology ·William W. Roberts, (unknown), Michael D. Fabrizio, Thomas W. Jarrett, Louis R. Kavoussi, Michael E. Moran, Bryan A. Mehlhaff, (unknown), Michael Grasso, J. Stuart Wolf, Glenn M. Preminger, Margaret S. Pearle, Raymond J. Leveillee, Robert G. Moore	3
18	Endoscopic Subcutaneous Neurovascular Lower-Extremity Myofascial Flap Harvesting for Genitourinary Reconstruction 1998 ·Journal of Endourology ·(unknown), Michael E. Moran, (unknown), Mark White, Pramod Reddy, Bryan A. Mehlhaff	4
19	Evaluation of Retropulsion Caused by Holmium: YAG Laser with Various Power Settings and Fibers 1998 ·Journal of Endourology ·Mark White, Michael E. Moran, (unknown), (unknown), Bryan A. Mehlhaff	69
20	Assessment of Access Strategies for Fetoscopic Urologic Surgery: Preliminary Results 1997 ·Journal of Endourology ·(unknown), Michael E. Moran, Bryan A. Mehlhaff, Barton L. Sachs, James Mandell	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact